



**Securities Investors Association (Singapore)**  
7 Maxwell Road #05-03 MND Building Annexe B Singapore 069111  
Tel: (65) 6227 2683 Email: [admin@sias.org.sg](mailto:admin@sias.org.sg)  
[www.sias.org.sg](http://www.sias.org.sg)  
UEN No: S99SS0111B  
GST Reg No: M90367530Y0Y

**Issuer:** AJJ Medtech Holdings Limited

**Stock code:** 584

**Meeting details:**

Date: 30 April 2026

Time: 10.00 a.m.

Venue: 8 Commonwealth Lane, #02-04 Grande Building, Singapore 149555

**Q1.** As noted in the chairman’s statement, FY2025 marks the fifth year since the group initiated its transition toward a healthcare technology platform in 2020. During the year, the group advanced several initiatives, including development collaboration for the HIT-1 humanoid eldercare robotics platform and the expansion of healthcare institutional partnerships.

The group has identified intelligent care robotics, renal care, and digital healthcare as its primary growth pillars. The renal care segment provides recurring revenue through equipment and consumables, while medical technology solutions and pharmaceutical products supporting the broader platform.

For FY2025, revenue increased by 37.4% to \$3.19 million, with gross profit rising to \$1.17 million. Loss after tax was \$(2.93) million.

- (i) Intelligent Eldercare Robot HIT-1: How was Huaxi Intelligent Technology selected as a technology partner? What operational milestones or commercial outcomes have been achieved to date? Would shareholders be able to interact with the robot at the AGM?**
- (ii) Renal care: What is the group’s value proposition in the haemodialysis segment, and how does management assess the impact of policy shifts towards peritoneal dialysis on demand and long-term viability?**
- (iii) Order book and revenue visibility: Can management provide a detailed breakdown of the approximately \$8 million order book, including contract types, counterparties, duration, and revenue recognition timelines?**

**Q2.** For two consecutive years, the company has announced material discrepancies between its unaudited and audited financial statements. The adjustments disclosed span multiple areas, including expense classification, liability classification, related party balances, and presentation of cash flow items.

Date & Time	Issuer Name	Security Name	Title	Category
15 Apr 2026 07:52 AM	AJJ MEDTECH HOLDINGS LIMITED	AJJ MEDTECH HOLDINGS LIMITED	Financial Statements and Related Announcement::Discrepancies between unaudited and audited accounts	Financial Statements
15 Apr 2026 07:50 AM	AJJ MEDTECH HOLDINGS LIMITED	AJJ MEDTECH HOLDINGS LIMITED	Financial Statements and Related Announcement::Auditor's Comments of Accounts	Financial Statements
27 Feb 2026 10:41 PM	AJJ MEDTECH HOLDINGS LIMITED	AJJ MEDTECH HOLDINGS LIMITED	Financial Statements and Related Announcement::Full Yearly Results	Financial Statements
12 Nov 2025 09:01 PM	AJJ MEDTECH HOLDINGS LIMITED	AJJ MEDTECH HOLDINGS LIMITED	Financial Statements and Related Announcement::Third Quarter Results	Financial Statements
07 Aug 2025 08:15 PM	AJJ MEDTECH HOLDINGS LIMITED	AJJ MEDTECH HOLDINGS LIMITED	Financial Statements and Related Announcement::Half Yearly Results	Financial Statements
15 May 2025 05:55 PM	AJJ MEDTECH HOLDINGS LIMITED	AJJ MEDTECH HOLDINGS LIMITED	Financial Statements and Related Announcement::First Quarter Results	Financial Statements
15 Apr 2025 06:13 PM	AJJ MEDTECH HOLDINGS LIMITED	AJJ MEDTECH HOLDINGS LIMITED	Financial Statements and Related Announcement::Discrepancies between unaudited and audited accounts	Financial Statements
15 Apr 2025 06:12 PM	AJJ MEDTECH HOLDINGS LIMITED	AJJ MEDTECH HOLDINGS LIMITED	Financial Statements and Related Announcement::Auditor's Comments of Accounts	Financial Statements
28 Feb 2025 06:19 PM	AJJ MEDTECH HOLDINGS LIMITED	AJJ MEDTECH HOLDINGS LIMITED	Financial Statements and Related Announcement::Full Yearly Results	Financial Statements

(Source: <https://www.sgx.com/securities/company-announcements?value=AJJ%20MEDTECH%20HOLDINGS%20LIMITED&type=company&pagesize=20&ANNC=ANNC17>; emphasis added)

The audit committee comprises Tan Lye Heng Paul (chairman), Chong Eng Wee and Toh Lim Kai.

- (i) **Can the audit committee provide a clear explanation of the root causes of these discrepancies, particularly in areas such as classification of liabilities and cash flow presentation, and explain why these issues were not identified and resolved prior to the release of the unaudited results?**
- (ii) **What specific challenges has the finance function faced in applying Singapore Financial Reporting Standards (International) (SFRS(I))?**

- (iii) What role did the AC play in the preparation and review of the financial statements, and does the AC consider that its oversight was adequate and sufficient in light of the recurring discrepancies?**
- (iv) What specific enhancements have been made to the group's financial reporting functions, internal controls and review mechanisms?**

**Q3.** The company disclosed that as at 31 December 2025, the group had accrued employee salaries totalling \$132,000 relating to unpaid wages. Subsequent to the year end, \$33,000 has been paid, leaving an outstanding balance of \$99,000.

Under the Employment Act, salaries are generally required to be paid at least monthly and within seven days after the end of the salary period. The non-payment of these accrued salaries represents a potential breach of the Employment Act.

At 31 December 2025 and at the date of these financial statements, there was no claims made by the employees and no penalties imposed by Ministry of Manpower. The directors are of the view that no material losses will arise in respect of this non-compliance.

- (i) Can the board clarify the circumstances leading to the unpaid salaries, including whether they arose from cash flow constraints?**
- (ii) Does the board consider the group to be operating with adequate liquidity, and what factors have contributed to the delay in salary payments despite relatively modest amounts outstanding?**
- (iii) How many employees are affected, what is the timeline for settling the remaining \$99,000, and what measures are being taken to ensure employees are paid in full and on time going forward?**
- (iv) What actions have the directors taken to address this issue, including strengthening internal controls and cash management processes, and how will the board ensure that compliance with employment regulations is consistently maintained? What is the board's assessment of potential reputational risks?**

*Shareholders are welcome to use and/or adapt the questions prepared by SIAS and to forward them to the company.*

Check out the latest questions on the annual reports of listed companies on [SIAS website](#)

Join our mailing list [here](#) to receive latest news and upcoming events.



**Securities Investors Association (Singapore)**  
7 Maxwell Road #05-03 MND Building Annexe B Singapore 069111  
Tel: (65) 6227 2683 Email: [admin@sias.org.sg](mailto:admin@sias.org.sg)  
[www.sias.org.sg](http://www.sias.org.sg)  
UEN No: S99SS0111B  
GST Reg No: M90367530Y0Y

